Avidity Biosciences (RNA)
(Delayed Data from NSDQ)
$44.48 USD
-1.17 (-2.56%)
Updated Sep 20, 2024 04:00 PM ET
After-Market: $44.49 +0.01 (0.02%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
RNA 44.48 -1.17(-2.56%)
Will RNA be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for RNA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for RNA
Company News for Aug 13, 2024
Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Misses Revenue Estimates
RNA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Crinetics Pharmaceuticals, Inc. (CRNX) Reports Q2 Loss, Misses Revenue Estimates
Avidity (RNA) Up 33% on Rare Muscle Disease Study Results
Coherus BioSciences (CHRS) Reports Q1 Loss, Misses Revenue Estimates
Other News for RNA
Cantor Fitzgerald Reaffirms Their Buy Rating on Avidity Biosciences (RNA)
Unveiling 7 Analyst Insights On Avidity Biosciences
RTW Biotech half-year net asset value rises amid "challenging markets"
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month
Dyne stock tumbles 31% amid drug updates, management changes